<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691362</url>
  </required_header>
  <id_info>
    <org_study_id>2020-316</org_study_id>
    <nct_id>NCT04691362</nct_id>
  </id_info>
  <brief_title>Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty</brief_title>
  <official_title>Study of the Noninferiority of an Oral vs Intravenous Administration of Tranexamic Acid in Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find noninferiority relationship between oral and intravenous administration of tranexamic&#xD;
      acid on peroperative and postoperative blood loss and serum concentration during primary&#xD;
      total hip arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid is an anti-fibrinolytic drug, recommended in total hip arthroplasty to reduce&#xD;
      peroperative and postoperative hemorrhagic complications. The original character of our study&#xD;
      lies in the serum dosage of tranexamic acid, allowing to correlate the primary objective&#xD;
      (blood loss) with this one. The investigators will focus on the reduction of the risks&#xD;
      associated with the administration of intravenous medicines, the economic aspect and the ease&#xD;
      of use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded randomized controlled trial. Patient, anesthesiologist and surgeon are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss</measure>
    <time_frame>First 48 hours after surgery</time_frame>
    <description>Peroperative (suction) and postoperative (drainage) total blood loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tranexamic acid</measure>
    <time_frame>2 hours after oral administration</time_frame>
    <description>Monitoring of serum dosage of tranxemaic acid in randomized subpopulation of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tranexamic acid</measure>
    <time_frame>6 hours after oral administration</time_frame>
    <description>Monitoring of serum dosage of tranxemaic acid in randomized subpopulation of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tranexamic acid</measure>
    <time_frame>30 minutes after intravenous administration</time_frame>
    <description>Monitoring of serum dosage of tranxemaic acid in randomized subpopulation of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tranexamic acid</measure>
    <time_frame>4 hours after intravenous administration</time_frame>
    <description>Monitoring of serum dosage of tranxemaic acid in randomized subpopulation of each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemoglobin variation</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Variation of serum hemoglobin between preoperative and postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemoglobin variation</measure>
    <time_frame>72 hours after surgery</time_frame>
    <description>Variation of serum hemoglobin between preoperative and postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of blood transfusion</measure>
    <time_frame>72 hours after surgery</time_frame>
    <description>Incidence of blood transfusion in two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic complications</measure>
    <time_frame>72 hours after surgery</time_frame>
    <description>Incidence of thromboembolic complications such as pulmonary embolism or deep venous thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalisation stay</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Difference between two groups of total hospitalisation days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Hemorrhage Postoperative</condition>
  <condition>Total Blood Loss</condition>
  <condition>Arthroplasty Complications</condition>
  <arm_group>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>128 patients scheduled for primary total hip arthroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>128 patients scheduled for primary total hip arthroplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Oral Product</intervention_name>
    <description>Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration</description>
    <arm_group_label>Oral Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration</description>
    <arm_group_label>Intravenous Tranexamic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - ASA physical status 1, 2 and 3 scheduled for primary total hip arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal failure with serum creatinine level higher than 1,40 mg/dL&#xD;
&#xD;
          -  Thromboembolic events in last 12 months before surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Congenital or acquired coagulation diseases&#xD;
&#xD;
          -  History of gastric surgery that could lead to malabsorption&#xD;
&#xD;
          -  Diabetic gastro-paresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Piette, MD</last_name>
    <phone>003242843824</phone>
    <email>piettenicolas@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Carella, MD</last_name>
      <phone>003242843658</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. Reg Anesth Pain Med. 2019 Jan;44(1):7-11. doi: 10.1136/rapm-2018-000024. Review.</citation>
    <PMID>30640647</PMID>
  </reference>
  <reference>
    <citation>Wu Y, Zeng Y, Hu Q, Li M, Bao X, Zhong J, Shen B. Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: A randomized clinical trial. Thromb Res. 2018 Nov;171:143-148. doi: 10.1016/j.thromres.2018.10.006. Epub 2018 Oct 6.</citation>
    <PMID>30312799</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Jean François Brichant</investigator_full_name>
    <investigator_title>Head of Anesthesiology Departement</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Exsanguination</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

